Workflow
天智航: 上海荣正企业咨询服务(集团)股份有限公司关于北京天智航医疗科技股份有限公司2023年限制性股票激励计划首次及预留授予部分第二个归属期符合归属条件之独立财务顾问报告

Core Viewpoint - The report confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. has met the vesting conditions, allowing for the allocation of shares to eligible participants [6][10][16]. Summary by Sections Definitions - The report defines key terms related to the incentive plan, including "restricted stock," "incentive objects," and "vesting conditions," which are essential for understanding the plan's framework [1][2]. Approval Process - The 2023 restricted stock incentive plan has undergone necessary approval procedures, including resolutions from the board of directors and the supervisory board, confirming the plan's compliance with relevant regulations [4][6]. Vesting Conditions Achievement - The board of directors has reviewed and confirmed that the vesting conditions for the second vesting period have been met, allowing for the allocation of 3.86466 million shares to 148 eligible participants [6][10]. Performance Requirements - The performance requirements for the incentive plan include achieving a revenue growth rate of at least 40% for the first vesting period and 90% for the second vesting period, or obtaining medical device registration for at least two new orthopedic surgical robots [10][11]. Allocation Details - For the first grant, 95 participants are eligible to receive 3.135355 million shares, while for the reserved grant, 117 participants are eligible for 729305 shares, both at a grant price of 8.66 yuan per share [12][14][15]. Independent Financial Advisor's Opinion - The independent financial advisor concludes that the vesting conditions have been met and that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [16].